A phase I study of AFNT-211, autologous CD4(+) and CD8(+) T cells engineered to express a high avidity HLA-A(*)11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors Meeting Abstract
| Authors: | Basu, S. K.; Khan, B.; Payumo, F.; Wan, R.; Chiorean, E. G.; Gahvari, Z.; Hecht, J. R.; Hurwitz, M. E.; Leidner, R. S.; Lenz, H. J.; Pelster, M.; Punekar, S. R.; Schoenfeld, A. J.; Zhao, D.; Nagorsen, D. |
| Abstract Title: | A phase I study of AFNT-211, autologous CD4(+) and CD8(+) T cells engineered to express a high avidity HLA-A(*)11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-01 |
| Start Page: | TPS2678 |
| Language: | English |
| ACCESSION: | WOS:001534389600001 |
| DOI: | 10.1200/JCO.2025.43.16_suppl.TPS2678 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
